Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects

Inclusion Criteria: * fasting triglycerides \>= 200 mg/dL but \<1,200 mg/dL * fasting LDL \<= 160 mg/dL * participation in a lipid-lowering diet and exercise program for at least 28 days * treatment with stable HAART consisting of first or second RTV-boosted PI regimen plus optimized background ART for at least 3 months * plasma HIV-1 RNA \<50 copies/mL * CD4+ cell count \>50 cells/mm3 * male subjection testosterone replacement therapy with total testosterone level \<= 1 x upper limit of normal * female study volunteer must use a form of contraception * ability and willing ness to give written informed consent Exclusion Criteria: * any Grade 4 laboratory abnormality * currently taking amprenavir or fosamprenavir * required a second RTV-boosted PI for reasons of virologic failure * atherosclerotic disease risk * congestive heart failure (NYHA Class III or IV) * uncontrolled hypertension * history of pancreatitis * active bleeding disorder * recent history of significant renal, pulmonary, biliary, hepatic or gastrointestinal disease * current diabetes mellitus requiring pharmacological treatment * use of systemic cancer chemotherapy; active cancer * pregnancy or breast-feeding * requirement for any lipid-lowering agent after baseline * use of hormonal anabolic therapies, systemic steroids, immune modulators * use of anticoagulants, investigational antiretroviral drugs * allergy to study drugs * active CDC clinical category C event